{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:30:11Z","timestamp":1794274211604,"version":"4.9.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.critrevonc.2021.103497","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T02:17:46Z","timestamp":1634609866000},"page":"103497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment"],"prefix":"10.1016","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1390-4191","authenticated-orcid":false,"given":"Giuseppe Carlo","family":"Iorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6300-1946","authenticated-orcid":false,"given":"Benjamin Oren","family":"Spieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Dal Pra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0005","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ijrobp.2009.12.025","article-title":"Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT","volume":"79","author":"Albuquerque","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0010","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.radonc.2015.10.027","article-title":"Scanning proton beam therapy reduces normal tissue exposure in pelvic radiotherapy for anal cancer","volume":"117","author":"Anand","year":"2015","journal-title":"Radiother Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0015","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.radonc.2017.01.020","article-title":"The feasibility of semi-automatically generated red bone marrow segmentations based on MR-only for patients with gynecologic cancer","volume":"123","author":"Andreychenko","year":"2017","journal-title":"Radiother Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103497_bib0020","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.3390\/cancers12113306","article-title":"Bone Marrow-Sparing IMRT in Anal Cancer Patients Undergoing Concurrent Chemo-Radiation: Results of the First Phase of a Prospective Phase II Trial","volume":"12","author":"Arcadipane","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0025","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ijrobp.2011.12.072","article-title":"Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal","volume":"84","author":"Bazan","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0030","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ijrobp.2013.09.017","article-title":"Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy","volume":"87","author":"Bazan","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103497_bib0035","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2307\/3579905","article-title":"Radiation-induced apoptosis in human lymphocytes and lymphoma cells critically relies on the up-regulation of CD95\/Fas\/APO-1 ligand","volume":"149","author":"Belka","year":"1998","journal-title":"Radiat. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103497_bib0045","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/jmri.24071","article-title":"Water-fat MRI for assessing changes in bone marrow composition due to radiation and chemotherapy in gynecologic cancer patients","volume":"38","author":"Bolan","year":"2013","journal-title":"J. Magn. Reson. Imaging"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0050","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0360-3016(02)03801-4","article-title":"Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies","volume":"54","author":"Brixey","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103497_bib0055","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/hed.23535","article-title":"Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer","volume":"36","author":"Campian","year":"2014","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijrobp.2014.05.041","article-title":"Fat composition changes in bone marrow during chemotherapy and radiation therapy","volume":"90","author":"Carmona","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0065","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/IGC.0000000000000660","article-title":"Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC","volume":"26","author":"Chang","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0070","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.prro.2013.07.011","article-title":"Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal","volume":"4","author":"Cheng","year":"2014","journal-title":"Pract. Radiat. Oncol."},{"issue":"244","key":"10.1016\/j.critrevonc.2021.103497_bib0075","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0080","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijrobp.2016.01.022","article-title":"Hematologic Toxicity in Patients Treated With Postprostatectomy Whole-Pelvis Irradiation With Different Intensity Modulated Radiation Therapy Techniques Is Not Negligible and Is Prolonged: Preliminary Results of a Longitudinal, Observational Study","volume":"95","author":"Cozzarini","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0085","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.adro.2019.06.005","article-title":"18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation","volume":"4","author":"David","year":"2019","journal-title":"Adv. Radiat. Oncol."},{"issue":"9747","key":"10.1016\/j.critrevonc.2021.103497_bib0090","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0095","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/cam4.2003","article-title":"Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort","volume":"8","author":"de Vries Schultink","year":"2019","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0100","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2010.06.042","article-title":"Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer","volume":"81","author":"Dibiase","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.radonc.2015.05.005","article-title":"Bone marrow sparing in intensity modulated proton therapy for cervical cancer: Efficacy and robustness under range and setup uncertainties","volume":"115","author":"Dinges","year":"2015","journal-title":"Radiother Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0110","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ijrobp.2004.07.676","article-title":"Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study","volume":"61","author":"Due\u00f1as-Gonz\u00e1lez","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0115","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2014.08.017","article-title":"[(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy","volume":"90","author":"Elicin","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0120","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.adro.2018.08.014","article-title":"Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors","volume":"3","author":"Ellsworth","year":"2018","journal-title":"Adv. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0130","first-page":"62","article-title":"Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study","volume":"35","author":"Erpolat","year":"2014","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0135","doi-asserted-by":"crossref","first-page":"123241","DOI":"10.1155\/2013\/123241","article-title":"Inflammation and immunity in radiation damage to the gut mucosa","volume":"2013","author":"Fran\u00e7ois","year":"2013","journal-title":"Biomed. Res. Int."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103497_bib0140","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12032-016-0789-x","article-title":"Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients","volume":"33","author":"Franco","year":"2016","journal-title":"Med. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103497_bib0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12032-016-0852-7","article-title":"Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation","volume":"33","author":"Franco","year":"2016","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0150","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1186\/s12885-017-3708-4","article-title":"Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation","volume":"17","author":"Franco","year":"2017","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0155","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/07357907.2018.1479413","article-title":"Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation","volume":"36","author":"Franco","year":"2018","journal-title":"Cancer Invest."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0160","series-title":"Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging","author":"GYN0007","year":"2021"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103497_bib0165","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cbf.1523","article-title":"Inhibitory effect of mesenchymal stem cells on lymphocyte proliferation","volume":"26","author":"Gao","year":"2008","journal-title":"Cell Biochem. Funct."},{"issue":"suppl_4","key":"10.1016\/j.critrevonc.2021.103497_bib0170","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0175","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2017.03.022","article-title":"Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer","volume":"98","author":"Goodman","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0180","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.6004\/jnccn.2015.0151","article-title":"Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors","volume":"13","author":"Grossman","year":"2015","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/aja.2011.102","article-title":"Hematological changes during androgen deprivation therapy","volume":"14","author":"Grossmann","year":"2012","journal-title":"Asian J. Androl."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103497_bib0190","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.clon.2011.04.014","article-title":"A population-based study of prostate cancer chemotherapy","volume":"23","author":"Harris","year":"2011","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103497_bib0195","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1097\/IGC.0000000000000292","article-title":"Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy","volume":"24","author":"Hui","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103497_bib0200","series-title":"Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer","author":"INTERTECC-3","year":"2021"},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103497_bib0205","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0210","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11547-015-0605-2","article-title":"A prospective phase II study of magnetic resonance imaging guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer","volume":"121","author":"Jianyang","year":"2016","journal-title":"Radiol. Med."},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2021.103497_bib0215","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/j.ijrobp.2017.06.351","article-title":"OSS-326: Higher Radiation Dose to Immune System is Correlated With Poorer Survival in Patients With Stage III Nonesmall Cell Lung Cancer: A Secondary Study of a Phase 3 Cooperative Group Trial (NRG Oncology RTOG 0617)","volume":"99","author":"Jin","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0220","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0225","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ijrobp.2018.04.033","article-title":"Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort","volume":"101","author":"Jones","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0230","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s13566-016-0270-7","article-title":"A comparison of dosimetric parameters in PET-based active bone marrow volume and total bone volume in prediction of hematologic toxicity in cervical cancer patients treated with chemoradiation","volume":"6","author":"Khullar","year":"2017","journal-title":"J. Radiat. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103497_bib0235","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/cncr.20270","article-title":"The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy","volume":"100","author":"Kim","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0240","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3857\/roj.2015.33.2.83","article-title":"Can we omit prophylactic inguinal nodal irradiation in anal cancer patients?","volume":"33","author":"Kim","year":"2015","journal-title":"Radiat. Oncol. J."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0245","doi-asserted-by":"crossref","first-page":"41","DOI":"10.21037\/tcr.2017.12.23","article-title":"Radiotherapy and radiochemotherapy increase serum levels of pro-inflammatory interleukin-6 and C-reactive protein in patients with head and neck cancers","volume":"7","author":"Kiprian","year":"2018","journal-title":"Transl. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0250","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijrobp.2013.01.017","article-title":"Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer","volume":"86","author":"Klopp","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0255","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ijrobp.2019.11.012","article-title":"Shifting the Curtain-Can We Make Sense of the Whole Pelvis Controversy?","volume":"106","author":"Koontz","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103497_bib0260","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s00066-020-01659-z","article-title":"Dose\u2013volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer","volume":"196","author":"Kuncman","year":"2020","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0265","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijrobp.2019.05.064","article-title":"Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy","volume":"105","author":"Ladbury","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0270","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semradonc.2019.12.003","article-title":"Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy","volume":"30","author":"Lambin","year":"2020","journal-title":"Semin. Radiat. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0275","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/A:1006106209527","article-title":"Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone","volume":"17","author":"Lange","year":"1998","journal-title":"Cancer Metastasis Rev."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0280","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","article-title":"An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone\/radiation interactions","volume":"69","author":"Lawton","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0285","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijrobp.2016.10.010","article-title":"Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors","volume":"97","author":"Lee","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0290","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.radonc.2020.07.026","article-title":"Significance of lymphocyte recovery from treatment-related lymphopenia in locally advanced pancreatic cancer","volume":"151","author":"Lee","year":"2020","journal-title":"Radiother Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0295","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2017.02.017","article-title":"Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer","volume":"123","author":"Li","year":"2017","journal-title":"Radiother Oncol."},{"issue":"54","key":"10.1016\/j.critrevonc.2021.103497_bib0300","doi-asserted-by":"crossref","first-page":"92904","DOI":"10.18632\/oncotarget.21646","article-title":"Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0305","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ijrobp.2009.11.062","article-title":"Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data","volume":"78","author":"Liang","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0310","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijrobp.2012.04.044","article-title":"Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies","volume":"85","author":"Liang","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103497_bib0315","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.4049\/jimmunol.169.8.4288","article-title":"IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha","volume":"169","author":"Liao","year":"2002","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103497_bib0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0325","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.hoc.2016.03.012","article-title":"Imaging of Bone Marrow","volume":"30","author":"Lin","year":"2016","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0330","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0360-3016(03)00521-2","article-title":"Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy","volume":"57","author":"Lujan","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1081","key":"10.1016\/j.critrevonc.2021.103497_bib0335","doi-asserted-by":"crossref","first-page":"20170398","DOI":"10.1259\/bjr.20170398","article-title":"Cervical cancer treated with reduced-volume intensity-modulated radiation therapy base on Sedlis criteria (NCCN VS RTOG)","volume":"91","author":"Luo","year":"2018","journal-title":"Br. J. Radiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0340","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1088\/0031-9155\/53\/1\/002","article-title":"A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD)","volume":"53","author":"Luxton","year":"2008","journal-title":"Phys. Med. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0345","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/1097-0142(197801)41:1<108::AID-CNCR2820410116>3.0.CO;2-Z","article-title":"Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation","volume":"41","author":"MacLennan","year":"1978","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103497_bib0350","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/IGC.0b013e3182664b46","article-title":"Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer","volume":"22","author":"Mahantshetty","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0355","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/s41467-020-15397-4","article-title":"Loss of testosterone impairs anti-tumor neutrophil function","volume":"11","author":"Markman","year":"2020","journal-title":"Nat. Commun."},{"issue":"3 Suppl","key":"10.1016\/j.critrevonc.2021.103497_bib0360","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0365","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0360-3016(94)00430-S","article-title":"Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy","volume":"31","author":"Mauch","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0370","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2016.04.009","article-title":"Using [(18)F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients","volume":"96","author":"McGuire","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0375","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.ijrobp.2006.03.018","article-title":"Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy","volume":"66","author":"Mell","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0380","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.ijrobp.2008.04.046","article-title":"Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer","volume":"71","author":"Mell","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0385","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ijrobp.2007.08.074","article-title":"Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy","volume":"70","author":"Mell","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0390","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ijrobp.2016.11.027","article-title":"Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2)","volume":"97","author":"Mell","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103497_bib0395","first-page":"2803","article-title":"Hematologic Toxicity of Conformal Radiotherapy and Intensity Modulated Radiotherapy in Prostate and Bladder Cancer Patients","volume":"19","author":"Miszczyk","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103497_bib0400","first-page":"5091","article-title":"A dosimetric analysis of intensity-modulated radiation therapy with bone marrow sparing for cervical cancer","volume":"34","author":"Murakami","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0405","article-title":"Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial","volume":"26","author":"Murthy","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0410","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/jcb.22699","article-title":"Differential effect of ionizing radiation exposure on multipotent and differentiation-restricted bone marrow mesenchymal stem cells","volume":"111","author":"Mussano","year":"2010","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0415","series-title":"Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers","author":"NRG-GY006","year":"2021"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0420","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.canrad.2016.05.011","article-title":"Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study","volume":"20","author":"Naik","year":"2016","journal-title":"Cancer Radiother"},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0425","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2307\/3577549","article-title":"Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay","volume":"123","author":"Nakamura","year":"1990","journal-title":"Radiat. Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0430","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ijrobp.2015.12.374","article-title":"Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy","volume":"94","author":"Newman","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0435","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.21037\/jtd.2020.03.93","article-title":"Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer","volume":"12","author":"Newman","year":"2020","journal-title":"J. Thorac. Dis."},{"issue":"Suppl 3","key":"10.1016\/j.critrevonc.2021.103497_bib0440","doi-asserted-by":"crossref","first-page":"E236","DOI":"10.1016\/j.ijrobp.2015.07.1143","article-title":"Vuong T. PV-2589: Radiation Induced Bone Marrow Toxicity in Prostate Cancer Patients, Treated With Adjuvant, Salvage or Radical Radiation Therapy","volume":"93","author":"Niazi","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0445","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ijrobp.2016.11.033","article-title":"Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy","volume":"97","author":"Noticewala","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0450","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.ijrobp.2011.02.010","article-title":"Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study)","volume":"82","author":"Ortholan","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0455","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103497_bib0460","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","article-title":"Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix","volume":"18","author":"Peters","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0465","first-page":"104","article-title":"Mesorectal radiotherapy for early stage rectal cancer: A novel target volume","volume":"21","author":"Peters","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103497_bib0470","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00066-015-0841-3","article-title":"Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity","volume":"191","author":"Pinkawa","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.critrevonc.2021.103497_bib0475","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13566-017-0329-0","article-title":"Absolute volume of active bone marrow and total bone marrow spared in anal cancer patients using intensity modulated proton versus volumetric arc therapy","volume":"7","author":"Prasad","year":"2018","journal-title":"J. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0480","article-title":"Bone Marrow Suppression during Postoperative Radiation for Bladder Cancer and Comparative Benefit of Proton Therapy\u2014Phase 2 Trial Secondary Analysis","author":"Press","year":"2021","journal-title":"Int. J. Part Ther."},{"issue":"333","key":"10.1016\/j.critrevonc.2021.103497_bib0485","doi-asserted-by":"crossref","first-page":"333ra47","DOI":"10.1126\/scitranslmed.aad5659","article-title":"Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse","volume":"8","author":"Pu","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0490","series-title":"A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy","author":"RTOG 0534","year":"2021"},{"key":"10.1016\/j.critrevonc.2021.103497_bib0495","series-title":"Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial","author":"RTOG 0924","year":"2021"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2021.103497_bib0500","doi-asserted-by":"crossref","first-page":"S332","DOI":"10.1016\/S0167-8140(18)30937-X","article-title":"PV-0627: Hematologic toxicity after whole-pelvis irradiation: results of a longitudinal observational study","volume":"127","author":"Rancati","year":"2018","journal-title":"Radiother Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0505","first-page":"70","article-title":"Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study","volume":"4","author":"Rattan","year":"2016","journal-title":"Ann. Transl. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0510","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/COC.0000000000000520","volume":"42","author":"Rice","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103497_bib0515","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2003.05.004","article-title":"Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413","volume":"21","author":"Roach","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103497_bib0520","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0525","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.radonc.2015.09.009","article-title":"Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer","volume":"117","author":"Robinson","year":"2015","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0530","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.radonc.2019.08.016","article-title":"Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer","volume":"143","author":"Robinson","year":"2020","journal-title":"Radiother Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2021.103497_bib0535","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0540","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2009.11.010","article-title":"Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy","volume":"79","author":"Rose","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0545","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ijrobp.2011.09.048","article-title":"Correlation between radiation dose to \u00b98F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy","volume":"83","author":"Rose","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103497_bib0550","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijrobp.2015.12.006","article-title":"Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation","volume":"94","author":"Rose","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0555","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.prro.2017.03.008","article-title":"Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation","volume":"7","author":"Rose","year":"2017","journal-title":"Pract. Radiat. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103497_bib0560","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s00066-017-1144-7","article-title":"Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients","volume":"193","author":"Sage","year":"2017","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0565","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00384-007-0382-z","article-title":"Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review","volume":"23","author":"Saif","year":"2008","journal-title":"Int. J. Colorectal Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0570","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13014-019-1223-2","article-title":"Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study","volume":"14","author":"Sanguineti","year":"2019","journal-title":"Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0575","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.adro.2019.01.005","article-title":"Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer","volume":"4","author":"Schad","year":"2019","journal-title":"Adv. Radiat. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103497_bib0580","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdg500","article-title":"Oral capecitabine as an alternative to i.v. 5-\ufb02uorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial","volume":"14","author":"Scheithauer","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0585","first-page":"30052","article-title":"PSMA-PET\/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy","author":"Schiller","year":"2020","journal-title":"Eur. Urol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0590","first-page":"139","article-title":"Anal cancer: current standards in care and recent changes in practice","volume":"65","author":"Shridhar","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0595","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.radonc.2015.11.020","article-title":"Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation","volume":"118","author":"Sini","year":"2016","journal-title":"Radiother Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0600","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.adro.2020.03.021","article-title":"Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma","volume":"5","author":"So","year":"2020","journal-title":"Adv. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0605","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2016.07.043","article-title":"Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage","volume":"71","author":"Spratt","year":"2017","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103497_bib0610","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103497_bib0615","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0360-3016(87)90046-0","article-title":"Fractionation and dose rate effects in mice: a model for bone marrow transplantation in man","volume":"13","author":"Tarbell","year":"1987","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0620","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.radonc.2016.07.017","article-title":"International consensus guidelines on Clinical Target Volume delineation in rectal cancer","volume":"120","author":"Valentini","year":"2016","journal-title":"Radiother Oncol."},{"issue":"51","key":"10.1016\/j.critrevonc.2021.103497_bib0625","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1016\/j.vaccine.2015.05.105","article-title":"In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment","volume":"33","author":"Vanpouille-Box","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2021.103497_bib0630","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","article-title":"A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors","volume":"123","author":"Venkatesulu","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103497_bib0635","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13014-015-0454-0","article-title":"Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?","volume":"10","author":"Wan","year":"2015","journal-title":"Radiat. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2021.103497_bib0640","doi-asserted-by":"crossref","first-page":"7219","DOI":"10.1002\/cam4.2601","article-title":"The volume of 99m Tc sulfur colloid SPET-defined active bone marrow can predict grade 3 or higher acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0645","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.radonc.2015.08.015","article-title":"Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C","volume":"117","author":"White","year":"2015","journal-title":"Radiother Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0650","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/COC.0b013e3182940ff9","article-title":"The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma","volume":"38","author":"Wild","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0655","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","article-title":"Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer","volume":"94","author":"Wild","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"Suppl. (9)","key":"10.1016\/j.critrevonc.2021.103497_bib0660","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/1097-0142(19850501)55:9+<2086::AID-CNCR2820551409>3.0.CO;2-1","article-title":"Biologic basis for altered fractionation schemes","volume":"55","author":"Withers","year":"1985","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0665","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.prro.2017.07.001","article-title":"Predicting severe hematologic toxicity from extended-field chemoradiation of para-aortic nodal metastases from cervical cancer","volume":"8","author":"Yan","year":"2018","journal-title":"Pract. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0670","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2014.09.002","article-title":"Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy","volume":"113","author":"Yang","year":"2014","journal-title":"Radiother Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0675","doi-asserted-by":"crossref","first-page":"515","DOI":"10.21037\/tcr.2018.05.04","article-title":"Dosimetric predictors of acute hematologic toxicity due to intensity-modulated pelvic radiotherapy with concurrent chemotherapy for pelvic cancer patients","volume":"7","author":"Yang","year":"2018","journal-title":"Transl. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0680","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.3747\/co.21.1903","article-title":"One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity","volume":"21","author":"Yeung","year":"2014","journal-title":"Curr. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103497_bib0685","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103497_bib0690","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1754-9485.12297","article-title":"Longitudinal study of acute haematologic toxicity in cervical cancer patients treated with chemoradiotherapy","volume":"59","author":"Zhu","year":"2015","journal-title":"J. Med. Imaging Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103497_bib0695","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2013.03.008","article-title":"Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control","volume":"87","author":"Zilli","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:39:02Z","timestamp":1760902742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821002845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":139,"alternative-id":["S1040842821002845"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103497","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103497"}}